Spark Therapeutics, Inc. (NASDAQ:ONCE) – Analysts at Cantor Fitzgerald raised their FY2017 EPS estimates for Spark Therapeutics in a research report issued to clients and investors on Wednesday. Cantor Fitzgerald analyst E. Piros now anticipates that the biotechnology company will post earnings of ($7.27) per share for the year, up from their previous forecast of ($7.84). Cantor Fitzgerald currently has a “Buy” rating on the stock. Cantor Fitzgerald also issued estimates for Spark Therapeutics’ FY2018 earnings at ($5.54) EPS.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.75) by $0.14. The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The company’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.04) earnings per share.

TRADEMARK VIOLATION WARNING: This story was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://theolympiareport.com/2017/08/28/spark-therapeutics-inc-to-post-fy2017-earnings-of-7-27-per-share-cantor-fitzgerald-forecasts-once.html.

Several other research analysts have also issued reports on ONCE. BMO Capital Markets restated an “outperform” rating and set a $89.00 price target (up previously from $69.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $60.00 to $100.00 in a report on Tuesday, August 8th. BidaskClub upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Cowen and Company restated an “outperform” rating and set a $95.00 price target (up previously from $75.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Finally, Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $82.32.

Shares of Spark Therapeutics (ONCE) opened at 80.37 on Monday. The company’s 50-day moving average is $71.59 and its 200-day moving average is $61.05. The company’s market capitalization is $2.51 billion. Spark Therapeutics has a one year low of $35.07 and a one year high of $83.19.

A number of hedge funds have recently bought and sold shares of ONCE. Teachers Advisors LLC increased its stake in Spark Therapeutics by 16.8% in the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 4,875 shares during the last quarter. Nationwide Fund Advisors increased its stake in Spark Therapeutics by 2.5% in the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock valued at $923,000 after buying an additional 414 shares during the last quarter. Wells Fargo & Company MN increased its stake in Spark Therapeutics by 131.8% in the first quarter. Wells Fargo & Company MN now owns 522,894 shares of the biotechnology company’s stock valued at $27,891,000 after buying an additional 297,277 shares during the last quarter. Tocqueville Asset Management L.P. increased its stake in Spark Therapeutics by 10.1% in the first quarter. Tocqueville Asset Management L.P. now owns 59,850 shares of the biotechnology company’s stock valued at $3,192,000 after buying an additional 5,500 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in Spark Therapeutics by 0.7% in the first quarter. American Century Companies Inc. now owns 488,519 shares of the biotechnology company’s stock valued at $26,058,000 after buying an additional 3,445 shares during the last quarter. 87.30% of the stock is owned by institutional investors and hedge funds.

In related news, CFO Stephen W. Webster sold 2,337 shares of Spark Therapeutics stock in a transaction on Monday, July 31st. The shares were sold at an average price of $71.12, for a total value of $166,207.44. Following the completion of the sale, the chief financial officer now owns 4,837 shares of the company’s stock, valued at approximately $344,007.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel Barge Joseph La sold 5,000 shares of Spark Therapeutics stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $55.00, for a total transaction of $275,000.00. Following the completion of the sale, the general counsel now directly owns 9,567 shares of the company’s stock, valued at approximately $526,185. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 360,660 shares of company stock valued at $25,495,351. Insiders own 7.30% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.